1335106-03-0

Basic information

• Product Name: SR 1001
• Synonyms: SR 1001;SR1001,N-{4-Methyl-5-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoroMethyl-ethyl)-phenylsulfaMoyl]-thiazol-2-yl}-acetaMide;N-(5-(N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)sulphamoyl)-4-methylthiazol-2-yl)acetamide;N-(5-{[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxy-2-propanyl)phenyl]sulfamoyl}-4-methyl-1,3-thiazol-2-yl)acetamide
• CAS NO: 1335106-03-0
• Molecular Formula: C₁₅H₁₃F₆N₃O₄S₂
• Molecular Weight: 477.4018392
• Mol File: 1335106-03-0.mol
• Article Data: 4

Chemical Properties

• Appearance: white to beige/
• Density: 1.640±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO: >5mg/mL
• PKA: 5.90±0.50(Predicted)
• Stability: Stable for 2 years from date of purchase as supplied. Protect from moisture. Solutions in DMSO may be stored at -20° for up to 3 months.
• CAS DataBase Reference: SR 1001(CAS DataBase Reference)
• NIST Chemistry Reference: SR 1001(1335106-03-0)
• EPA Substance Registry System: SR 1001(1335106-03-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 1335106-03-0(Hazardous Substances Data)

Usage

Description

SR1001 (1335106-03-0) is a high affinity synthetic ligand for both RORα and RORγt acting as an inverse agonist. It binds specifically to the ligand-binding domain, inducing a conformational change which leads to diminished affinity for co-activators and increased affinity for co-repressors resulting in suppression of transcriptional activity.1?SR-1001 inhibits the development of murine TH17 cells2 and suppresses the expression of cytokines1. Suppresses insulitis and prevents hyperglycemia in a type 1 diabetes mouse model.3 Protects against pathologic neovascularization in various mouse models of retinopathy.4?Active in vivo

Uses

SR 1001 is a selective RORc inverse agonist.

References

1) Solt et al. (2011) Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand; Nature, 472 491 2) Beurel et al. (2013) Inflammatory T helper 17 cells promote depression-like behavior in mice; Biol. Psychiatry, 73 622 3) Solt et al. (2015) ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes; Endocrinology, 156 869 4) Sun et al. (2015) Nuclear receptor RORα regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation; Proc. Natl. Acad. Sci. USA, 112 10401

Upstream product

• 722-92-9 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 69812-29-9 2-acetamido-4-methyl-5-thiazolesulfonyl chloride 
• 62-53-3 aniline 

Relevant articles and documents

Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand

T-helper cells that produce interleukin-17 (TH 17 cells) are a recently identified CD4+ T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors

Structure-based design of substituted hexafluoroisopropanol- arylsulfonamides as modulators of RORc

The structure-activity relationships of T0901317 analogs were explored as RORc inverse agonists using the principles of property- and structure-based drug design. An X-ray co-crystal structure of T0901317 and RORc was obtained and provided molecular insight into why T0901317 functioned as an inverse agonist of RORc; whereas, the same ligand functioned as an agonist of FXR, LXR, and PXR. The structural data was also used to design inhibitors with improved RORc biochemical and cellular activities. The improved inhibitors possessed enhanced selectivity profiles (rationalized using the X-ray crystallographic data) against other nuclear receptors.